Cardiovascular research in France: Evolution of scientific activities and production over the last decade.


Journal

Archives of cardiovascular diseases
ISSN: 1875-2128
Titre abrégé: Arch Cardiovasc Dis
Pays: Netherlands
ID NLM: 101465655

Informations de publication

Date de publication:
Apr 2019
Historique:
received: 12 11 2018
accepted: 12 11 2018
pubmed: 15 1 2019
medline: 14 6 2019
entrez: 15 1 2019
Statut: ppublish

Résumé

Cardiovascular disease (CVD) is a major cause of death worldwide, and fruitful research is needed for future advances in this field. To analyse the scientific production and vitality of French cardiovascular clinical research, and its evolution over the last decade. We first used Lab Times online data obtained through the Web of Science (Thomson-Reuters, Toronto, ON, Canada), then the PubMed database (National Center for Biotechnology Information [NCBI], Bethesda, MD, USA), for studies published between 2005 and 2015 in the multidisciplinary and cardiology journals with the highest impact factors. French abstracts submitted and accepted at the European Society of Cardiology (ESC) congress were provided directly by the ESC. The number of cardiovascular projects was analysed through the http://www.ClinicalTrials.gov database and the French site for government-funded projects, over the decade from 2008 to 2017. Overall, France was ranked fifth in Europe and eighth worldwide for CVD publications. During the 10-year period from 2005 to 2015, French publications accounted for 0.2-0.3% of articles in top multidisciplinary journals and 2% of articles in top cardiology journals. We observed a steady decrease in French abstract submissions at the ESC congress (from 5% to 3.5% in 10 years), and in 2017, France was ranked eighth in Europe. Across European countries, France has been ranked first for declared cardiovascular research on http://www.ClinicalTrials.gov over the last 3 years, for both interventional and observational studies. Regarding the Hospital Programme of Clinical Research, heart ranked second after neurosciences. France is very well represented in terms of new CVD projects, but actual French scientific production scores poorly. Investing in CVD research is a priority to increase the level of publication and to compete with other leading countries.

Sections du résumé

BACKGROUND BACKGROUND
Cardiovascular disease (CVD) is a major cause of death worldwide, and fruitful research is needed for future advances in this field.
AIMS OBJECTIVE
To analyse the scientific production and vitality of French cardiovascular clinical research, and its evolution over the last decade.
METHODS METHODS
We first used Lab Times online data obtained through the Web of Science (Thomson-Reuters, Toronto, ON, Canada), then the PubMed database (National Center for Biotechnology Information [NCBI], Bethesda, MD, USA), for studies published between 2005 and 2015 in the multidisciplinary and cardiology journals with the highest impact factors. French abstracts submitted and accepted at the European Society of Cardiology (ESC) congress were provided directly by the ESC. The number of cardiovascular projects was analysed through the http://www.ClinicalTrials.gov database and the French site for government-funded projects, over the decade from 2008 to 2017.
RESULTS RESULTS
Overall, France was ranked fifth in Europe and eighth worldwide for CVD publications. During the 10-year period from 2005 to 2015, French publications accounted for 0.2-0.3% of articles in top multidisciplinary journals and 2% of articles in top cardiology journals. We observed a steady decrease in French abstract submissions at the ESC congress (from 5% to 3.5% in 10 years), and in 2017, France was ranked eighth in Europe. Across European countries, France has been ranked first for declared cardiovascular research on http://www.ClinicalTrials.gov over the last 3 years, for both interventional and observational studies. Regarding the Hospital Programme of Clinical Research, heart ranked second after neurosciences.
CONCLUSIONS CONCLUSIONS
France is very well represented in terms of new CVD projects, but actual French scientific production scores poorly. Investing in CVD research is a priority to increase the level of publication and to compete with other leading countries.

Identifiants

pubmed: 30639381
pii: S1875-2136(18)30194-3
doi: 10.1016/j.acvd.2018.11.003
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

241-252

Informations de copyright

Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Auteurs

Claire Bouleti (C)

Inserm U1148, Department of Cardiology, hôpital Bichat, AP-HP, 6, rue Henri-Huchard, 75018 Paris, France.

Nicolas Danchin (N)

Department of Cardiology, Paris-Descartes University, hôpital Européen Georges-Pompidou, AP-HP, 75015 Paris, France.

Bernard Iung (B)

Inserm U1148, Department of Cardiology, hôpital Bichat, AP-HP, 6, rue Henri-Huchard, 75018 Paris, France; DHU FIRE Paris-Diderot University, Sorbonne Paris Cité, 75013 Paris, France. Electronic address: bernard.iung@aphp.fr.

Claude Daubert (C)

U1099, LTSI-Inserm, université de Rennes, 35043 Rennes, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH